Active, Not Recruiting
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
NCT05309668
- Conditions
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, Heredodegenerative Disorders, Nervous System, +14 more
- Locations
-
- Research Site Akron, Ohio, United States
- Research Site Philadelphia, Pennsylvania, United States
- Research Site Houston, Texas, United States
- Research Site Richmond, Virginia, United States